balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
D6402C00012
Phase 3 small_molecule active
Quick answer
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg for Heart Failure and Impaired Kidney Function is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Heart Failure and Impaired Kidney Function
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active